Home > Analytics > SYNCOM FORMULATIONS (INDIA)

SYNCOM FORMULATIONS (INDIA)
Intrinsic Value | Fundamental Analysis

BOM : 524470     NSE : SYNCOMF    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : None or < 25%
Nov 01,2024
Price(EOD): ₹ 20.83
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 1,958.02 Cr
Value of ₹ 1 Lac invested in SYNCOM FORMULATIONS (INDIA)
on Nov 04,2019 (price: ₹ 0.68)

₹ 1 L

₹ 30.63 L

1W : 6.7% 1M : -2.3% 1Y : 140.6%
COMMUNITY POLL
for SYNCOM FORMULATIONS (INDIA)
Please provide your vote to see the results
SYNCOM FORMULATIONS (INDIA) is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks
Industry Peers & Returns1W1M1Y
SYNCOM FORMULATIONS (INDIA) 6.7% -2.3% 140.6%
SUN PHARMACEUTICAL INDUSTRIES -2.3% -2.9% 69.8%
CIPLA 3.7% -5.9% 29.5%
DR REDDYS LABORATORIES -4.1% -6.6% 18.8%
ZYDUS LIFESCIENCES -0.3% -6.1% 74.6%
DIVIS LABORATORIES 1.6% 8.7% 74%
MANKIND PHARMA 10.8% 6.3% 53.2%
TORRENT PHARMACEUTICALS -3.2% -5.4% 66.1%
LUPIN -0.3% 0.7% 93.8%

FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)

 
Fundamentals Score
[ Q(TTM): Jun2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 SYNCOMF is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF SYNCOM FORMULATIONS (INDIA)

 
Valuation Score
[As on : Nov 01,2024 ]

Ratio Consolidated
P/E
P/B
P/S
68.58
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 28.55 Cr
[Latest Qtr - Jun2024 - Consolidated Results ]

6.8
P/B Calculated based on Book Value of Rs 288.14 Cr
[Latest Year - Mar2024 - Consolidated Results ]

6.73
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 290.81 Cr
[Latest Qtr - Jun2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 9% undervalued companies ! Discover More →

FAIR VALUE OF SYNCOM FORMULATIONS (INDIA)

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
444%
150%
154%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)



SYNCOM FORMULATIONS (INDIA) vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SYNCOM FORMULATIONS (INDIA)

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.25
0.32
0.27
0.28
0.25
0.32
0.27
0.28
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SYNCOM FORMULATIONS (INDIA)

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SYNCOM FORMULATIONS (INDIA)

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
17.01%
10.93%
0.74%
3.11%
45.82%
61.83%
65.3%
73.64%
QtrlyTrend
8
Latest Qtr: Jun2024
Quarterly Result Analysis →


SYNCOM FORMULATIONS (INDIA) related INDICES

BSE Indices1W1M1Y
S&P BSE SMALL CAP 6.3% -3.2% 50.7%
S&P BSE MIDSMALLCAP 4.1% -4.8% 49.7%
S&P BSE HEALTHCARE 3% -0.4% 61%
S&P BSE ALLCAP 1.8% -5.8% 36%
No NSE index found

You may also like the below Video Courses


FAQ about SYNCOM FORMULATIONS (INDIA)


Is SYNCOM FORMULATIONS (INDIA) good for long term investment?

As on Nov 01,2024, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Strong and hence it may be good for long term investment! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?

As on Nov 01,2024, SYNCOM FORMULATIONS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?

As on Nov 01,2024, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 8.20 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 3.83
Fair Value [Median EV / Sales Model] : Rs. 8.34
Fair Value [Median Price / Sales Model] : Rs. 8.20
Estimated Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 8.20

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SYNCOM FORMULATIONS (INDIA) trading at a Premium or Discount?

As on Nov 01,2024, SYNCOM FORMULATIONS (INDIA) is trading at a Premium of 154% based on the estimates of Median Intrinsic Value!